Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the trea™ent of patients with colon cancer, lung cancer, glioblastoma, renal-cell carcinoma, and age-related macular degeneration. As angiogenesis inhibitor, Bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
GenScript Anti-Bevacizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Bevacizumab.